An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2

The clinical utility of human interleukin-2 (hIL-2) is limited by its short serum half-life, preferential activation of regulatory T (T(Reg)) over immune effector cells, and dose-limiting toxicities. We previously engineered F10 immunocytokine (IC), an intramolecularly assembled cytokine/antibody fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Silver, Aliyah B., Tzeng, Stephany Y., Lager, Mallory, Wang, Jeremy, Ishihara, Jun, Green, Jordan J., Spangler, Jamie B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694763/
https://www.ncbi.nlm.nih.gov/pubmed/37992685
http://dx.doi.org/10.1016/j.xcrm.2023.101289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694763/
https://www.ncbi.nlm.nih.gov/pubmed/37992685
http://dx.doi.org/10.1016/j.xcrm.2023.101289

Ejemplares similares